Sanofi (SNY) has released an update.
Sanofi’s Dupixent has shown promising results in a pivotal study, achieving significant improvements in disease remission and symptom reduction for patients with moderate-to-severe bullous pemphigoid (BP), a chronic skin condition. The study revealed that patients on Dupixent were five times more likely to achieve sustained disease remission compared to those on a placebo. These results may pave the way for Dupixent to become the first targeted medicine for BP treatment in the U.S. and European Union.
For further insights into SNY stock, check out TipRanks’ Stock Analysis page.
